• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zynex Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    3/27/25 5:25:43 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ZYXI alert in real time by email
    0000846475false00008464752025-03-272025-03-27

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): March 27, 2025

    ​

    ​

    Zynex, Inc.

    (Exact Name of Registrant as Specified in its Charter)

    ​

    ​

           Nevada       

    001-38804

    90-0275169

    (State or other jurisdiction
    of incorporation)

    Commission File
    Number

    (I.R.S. Employer Identification number)

    ​

    ​

    9655 Maroon Circle, Englewood, CO 80112

    (Address of principal executive offices)  (Zip Code)

    ​

    Registrant's telephone number, including area code:   (800) 495-6670

    ​

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    d

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    ​

    Title of each class

    Ticker symbol(s)

    Name of each exchange on which
    registered

    Common Stock, $0.001 par value per share

    ZYXI

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

    ​

    ITEM 4.01Changes in Registrant’s Certifying Accountant

    ​

    On March 26, 2025, Zynex, Inc. (the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the Company’s independent registered accounting firm. On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum. On March 26, 2025, following the approval of the Audit Committee of the Company’s Board of Directors, CBIZ was engaged, effective immediately, as the Company’s independent registered public accounting firm for the year ended December 31, 2025.

    The reports of Marcum regarding the Company’s financial statements for the years ended December 31, 2024 and December 31, 2023, did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

    During the years ended December 31, 2024 and December 31, 2023, and through March 26, 2025, the date of Marcum’s resignation, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to such disagreement in its report and (b) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), except for:

    ●The material weakness in the Company’s internal control over financial reporting as reported in Part II, Item 9A of the Company’s Annual Report on Form 10-K for the years ended December 31, 2024 and 2023, as filed with the Securities and Exchange Commission (the “SEC”) on March 11, 2025 and March 12, 2024, respectively, related to Information Technology General Controls (“ITGCs”) that were not designed and operating effectively.
    ●The material weakness in the Company’s internal control over financial reporting as initially reported in Part II, Item 9A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 12, 2024, related to a material weakness in the design and operating effectiveness around the valuation of certain accounts receivables. In 2024, the Company completed the redesign of the failed controls over the valuation of certain accounts receivable and performed the necessary design walkthroughs and testing. The Company concluded the redesigned control was designed and operated as intended for the year ended December 31, 2024.

    The above reportable events were discussed between the Audit Committee and Marcum. Marcum has been authorized by the Company to respond fully to the inquiries of CBIZ, the successor independent registered public accounting firm, concerning these reportable events.

    During the years ended December 31, 2024 and December 31, 2023, and through March 26, 2025, the date Marcum informed the Company of their resignation, neither the Company nor anyone on the Company’s behalf consulted with CBIZ regarding (i) the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by CBIZ on the Company’s financial statements, and CBIZ did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any such accounting, auditing, or financial reporting issue or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions), as that term is described in Item 304(a)(1)(iv) of Regulation S-K, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K.

    The Company provided Marcum with a copy of this Current Report on Form 8-K prior to its filing with the U.S. Securities and Exchange Commission (the “SEC”) and requested that Marcum furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements made by us in response to Item 304(a) of Regulation S-K and, if it does not agree, the respects in which it does not agree, as required under Item 304(a)(3) of Regulation S-K. A copy of Marcum’s letter, dated March 27, 2025, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.

    ​

    ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS

    ​

    (d)       Exhibits

    ​

    Exhibit No.Description

    16.1Letter from Marcum LLP to the Securities and Exchange Commission dated March 27, 2025.

    104Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    ​

    ​

    Dated: March 27, 2025ZYNEX, INC.

    ​

    /s/ Dan Moorhead____________________________

    Dan Moorhead

    Chief Financial Officer

    ​

    ​

    ​

    Get the next $ZYXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYXI

    DatePrice TargetRatingAnalyst
    8/1/2025$3.70Neutral → Buy
    Ladenburg Thalmann
    8/1/2025Buy → Neutral
    H.C. Wainwright
    3/12/2025$11.00 → $5.50Outperform → Sector Perform
    RBC Capital Mkts
    3/12/2025Buy → Neutral
    Ladenburg Thalmann
    10/16/2023$13.00Outperform
    RBC Capital Mkts
    1/6/2023$10.00 → $18.00Neutral → Overweight
    Piper Sandler
    2/28/2022$15.50 → $10.00Buy
    B. Riley Securities
    2/25/2022$22.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ZYXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zynex Financial Restructuring Puts Company on Path to Long-Term Success

    ENGLEWOOD, Colo., Dec. 16, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation today announced it has voluntarily entered into a Chapter 11 court-supervised financial restructuring with the support of new financing from the Company's lenders. "Today we take the next step in creating a new future for Zynex," said Steven Dyson, Chief Executive Officer. "This financing demonstrates the confidence our lenders have in our business and

    12/16/25 8:00:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Reports Third Quarter 2025 Financial Results

    ENGLEWOOD, Colo., Nov. 17, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, and rehabilitation, today reported its financial and operational results for the third quarter ended September 30, 2025. Management Commentary and Recent Events "Since joining the Company in August, the new management team has worked tirelessly to address the business and compliance challenges at Zynex while creating a new future for all our company," said Steven Dyson,

    11/17/25 5:15:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success. Zynex has engaged Province, LLC, an internationally recognized financial advisory firm, to assist on evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies. In add

    11/14/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    SEC Filings

    View All

    Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - ZYNEX INC (0000846475) (Filer)

    12/18/25 4:30:11 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ZYNEX INC (0000846475) (Filer)

    12/16/25 8:09:16 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Zynex Inc.

    10-Q - ZYNEX INC (0000846475) (Filer)

    11/17/25 5:21:57 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Aronzon Paul

    3 - ZYNEX INC (0000846475) (Issuer)

    11/20/25 8:58:24 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Wise Bret W

    3 - ZYNEX INC (0000846475) (Issuer)

    10/17/25 9:46:04 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Bajaj Vikram Singh

    3 - ZYNEX INC (0000846475) (Issuer)

    9/3/25 6:19:15 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Disbrow Joshua R. bought $58,233 worth of shares (7,000 units at $8.32), increasing direct ownership by 11% to 72,000 units (SEC Form 4)

    4 - ZYNEX INC (0000846475) (Issuer)

    7/30/24 6:25:26 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zynex upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Zynex from Neutral to Buy and set a new price target of $3.70

    8/1/25 8:25:35 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Zynex from Buy to Neutral

    8/1/25 8:12:40 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Zynex from Outperform to Sector Perform and set a new price target of $5.50 from $11.00 previously

    3/12/25 7:36:55 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Zynex Inc. (Amendment)

    SC 13D/A - ZYNEX INC (0000846475) (Subject)

    5/24/23 6:26:30 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Leadership Updates

    Live Leadership Updates

    View All

    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success. Zynex has engaged Province, LLC, an internationally recognized financial advisory firm, to assist on evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies. In add

    11/14/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair

    ENGLEWOOD, Colo., Oct. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise to its Board of Directors. Mr. Wise will also serve as Chair of the Audit Committee. "Bret Wise is a great addition to our Board of Directors as the Chair of our Audit Committee as we continue to refocus the Zynex mission and vision around patient and customer success with a renewed comm

    10/14/25 6:07:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles

    ENGLEWOOD, Colo., Aug. 18, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new leaders at the Company.  On June 30, 2025, the Company announced the Board's appointment of Steven Dyson as the incoming CEO.  Since that time, Mr. Dyson and Thomas Sandgaard, the Chairman of the Board, have been actively working wi

    8/18/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Financials

    Live finance-specific insights

    View All

    Zynex Reports Third Quarter 2025 Financial Results

    ENGLEWOOD, Colo., Nov. 17, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, and rehabilitation, today reported its financial and operational results for the third quarter ended September 30, 2025. Management Commentary and Recent Events "Since joining the Company in August, the new management team has worked tirelessly to address the business and compliance challenges at Zynex while creating a new future for all our company," said Steven Dyson,

    11/17/25 5:15:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Sets Third Quarter 2025 Earnings Call

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, will hold a conference call on Tuesday, November 18, 2025 at 9:00 AM Eastern Time to discuss its financial results for the third quarter ended September 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call. Date: Tuesday, November 18, 2025Time: 9:00 AM Eastern Time (7:00 PM Moun

    11/14/25 8:00:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Reports Second Quarter 2025 Financial Results

    ENGLEWOOD, Colo., July 31, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary  "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily thro

    7/31/25 4:01:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care